Key facts
- This page summarizes David Linetsky's Form 4 filing for Phreesia, Inc. (PHR).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Apr 2025, 19:06.
David Linetsky - 21 Feb 2020 Form 4 Insider Report for Phreesia, Inc. (PHR)
- Reporting relationship
- SVP, Life Sciences
- Issuer ticker
- PHR
- Reported as of
- 21 Feb 2020
- Net transaction value
- +$2,491
- SEC form
- 4
- Accepted by SEC
- 08 Apr 2025, 19:06:41 UTC
- Prior SEC filing
- 10 Sep 2021
- Next SEC filing
- 10 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Allison Hoffman by Power of Attorney for David Linetsky
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Linetsky filed Form 4 for Phreesia, Inc. (PHR) on 08 Apr 2025.
Change
- Previous filing in this sequence was filed on 10 Sep 2021.
- Current net transaction value: +$2,491.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHR
transaction
Common Stock
Options Exercise
- Transaction value
- $2,491
- Shares
- +3,413
- Change %
- +1.6%
- Price
- $0.7300
- Shares after
- 219,250
- Date
- 21 Feb 2020
- Ownership
- Direct
- Footnotes
- F1, F2
PHR
transaction
Common Stock
Award
- Transaction value
- Shares
- +6,432
- Change %
- +2.9%
- Price
- Shares after
- 225,682
- Date
- 04 Apr 2025
- Ownership
- Direct
- Footnotes
- F2, F3
PHR
transaction
Common Stock
Award
- Transaction value
- Shares
- +536
- Change %
- +6.1%
- Price
- Shares after
- 9,260
- Date
- 04 Apr 2025
- Ownership
- By Spouse
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PHR
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -3,413
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 21 Feb 2020
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,413
- Exercise price
- $0.7300
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Reflects an option exercise that was not previously reported due to a vendor administrative oversight. Forms 4 filed after the date of exercise underreported total common stock holdings by 3,413 shares.
Footnote F2
The total in Column 5 has been adjusted to correct an overstatement of holdings by 2,298 shares first reflected in a Form 4 filed on May 5, 2021.
Footnote F3
Represents Restricted Stock Units ("RSUs") that were fully vested as of the grant date. These RSUs represent awards received in lieu of 50% of the Reporting Person's cash bonus earned for the fiscal year ending January 31, 2025 under the Issuer's Senior Executive Cash Incentive Bonus Plan. The Reporting Person elected to convert such portion of his cash bonus into RSUs representing 115% of the earned cash bonus amount. The number of RSUs granted is based on a per share value of $24.31, the closing price of the Issuer's common stock on April 4, 2025.
Footnote F4
This option was fully vested and exercisable as of the date of the reported transaction.